Opinion|Videos|April 11, 2025
Navigating Patient Factors When Deciding Treatment for a 38-Year-Old Woman With Severe Atopic Dermatitis
Panelists discuss how individual patient characteristics, including comorbidities, treatment history, and personal preferences, guide therapeutic decision-making for a 38-year-old woman with severe atopic dermatitis.
Advertisement
Advertisement
Related to this article
Find out what skin care products and aesthetic innovations clinicians are recommending to patients for the month of September.
Three experimental hair loss mechanisms are moving through late-stage trials for the first time in decades, and the data are worth knowing before patients ask.
Alexandra Charrow, MD, discussed biologic selection, deroofing, and emerging procedural approaches to hidradenitis suppurativa at Maui Derm NP+PA Fall 2026.
Week 28 data from the phase 2a EVERLAST-A trial showed PASI 100 responses increased to 71.4% despite no additional ORKA-001 dosing after week 4.
Immunovant will discontinue development of imeroprubart in cutaneous lupus erythematosus after the phase 2b study failed to meet its primary endpoint.
This review of the latest dermatological studies includes insights on
Both barzolvolimab doses improved UAS7 at week 12 in EMBARQ-CSU1 and EMBARQ-CSU2, with up to 54% of patients reaching complete response by week 24.
The designation marks the first FDA Fast Track status granted to a therapy for peeling skin syndrome, which currently has no approved treatment.
Advertisement
Advertisement
Trending on Dermatology Times
1
FAQ: Everything Clinicians (and Their Patients) Want to Know About the Hair Loss Pipeline
2
Barzolvolimab Achieves All Phase 3 End Points in Chronic Spontaneous Urticaria
3
ORKA-001 Achieves Deepening Skin Clearance Through Week 28 in Plaque Psoriasis
4
National APP Week: Donna Lam Cahill, PA-C, on Persistence, Patient Advocacy, and Finding a Career in Dermatology
5